Michelle Carr, Author at BioTuesdays

Executive Moves

Ripple Therapeutics appoints renowned ophthalmologist Dr. Jonathan Talamo to board

Closely-held Ripple Therapeutics named Jonathan Talamo, M.D., an internationally known ophthalmologist, innovator and consultant to the industry with more than 25 years of experience in healthcare, to the board. Dr...

May 4, 2021

Developments

Three finalists named for 2021 Bloom Burton Award

Daniel Durocher, Ph.D., scientific co-founder of Repare Therapeutics; Carl Hansen, Ph.D., founder and CEO of AbCellera; and Hamed Shahbazi, chairman and CEO of WELL Health Technologies are the three finalists for the...

April 27, 2021

Developments

Seelos receives positive EMA orphan drug opinion for SLS-005 in ALS

Seelos Therapeutics (NASDAQ:SEEL) received a positive opinion on European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the EMA committee for orphan medicinal products. The positive...

April 20, 2021

Developments

MiMedx announces last patient visits in 3 late-stage musculoskeletal trials

MiMedx Group (NASDAQ:MDXG) announced that the last patients have completed their last clinical visits in two late-stage IND trials: Phase 3 studies of AmnioFix injectable as a potential treatment for plantar fasciitis...

April 19, 2021

Markets

Citi transfers coverage of 111 Inc. with $16 PT

Citi Research transferred coverage of 111 Inc. (NASDAQ:YI) to Zoe Bian from Cui Cui, retaining a “buy/high risk” rating and price target of $16. Citi recently raised its price target to $16 from $12. The stock closed at...

April 19, 2021

Executive Moves

Former U.S. assistant secretary for health Admiral Joxel Garcia joins Flurotest advisory board

Former U.S. assistant secretary for health and four-star Admiral Joxel Garcia, M.D. joined FluroTest’s (TSXV:TEST; OTCQB:FLURF) advisory board. Dr. Garcia will help support FluroTest business operations...

April 6, 2021

Developments

Hepion Pharma reports new positive nonclinical antifibrotic data with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results from an in vivo study of CRV431 in a diet-induced animal model of non-alcoholic fatty liver disease (DIAMOND). Hepion’s CRV431 administered orally and once...

March 23, 2021

Developments

Diabeloop, BIOCORP in personalized diabetes management pact

Diabeloop and BIOCORP (FR0012788065 – ALCOR) are collaborating to offer new, simple and personalized treatment options to people living with diabetes. BIOCORP has developed and markets Mallya, an intelligent sensor for...

March 22, 2021

Developments

111 Inc. posts 96.1% jump in Q4 net revenue; beating guidance

Shanghai-based 111 Inc. (NASDAQ:YI) reported net revenue of $405.1-million (U.S.) in the fourth quarter of 2020, which was up 96.1%, from the year earlier quarter, beating its previous guidance of 81% to 90% growth. Net...

March 18, 2021

Developments

111, Inc. achieves full distribution coverage across mainland China

111, Inc. (NASDAQ:YI) opened two new state-of-the-art, technology-driven fulfillment centers in the Northern cities of Xi’an and Shenyang, bringing the company’s total number of fulfillment centers to eight. The...

March 16, 2021

Author - Michelle Carr

Ripple Therapeutics appoints renowned ophthalmologist Dr. Jonathan Talamo to board

Three finalists named for 2021 Bloom Burton Award

Seelos receives positive EMA orphan drug opinion for SLS-005 in ALS

MiMedx announces last patient visits in 3 late-stage musculoskeletal trials

Citi transfers coverage of 111 Inc. with $16 PT

Former U.S. assistant secretary for health Admiral Joxel Garcia joins Flurotest advisory board

Hepion Pharma reports new positive nonclinical antifibrotic data with CRV431

Diabeloop, BIOCORP in personalized diabetes management pact

111 Inc. posts 96.1% jump in Q4 net revenue; beating guidance

111, Inc. achieves full distribution coverage across mainland China

General

More